News
ESSA Provides Update on Court Hearing
ESSA Provides Update to the Acquisition of Realm Therapeutics
ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders
ESSA Pharma to Hold Annual Shareholders’ Meeting and Announces Three Realm-Nominated Directors
Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics – Acquisition Expected to be Completed by Mid-Year 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019.
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting
ESSA Pharma Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2019
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer